Official Title

A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Purpose

The purpose of this study is to continue collection of long-term information about pembrolizumab (MK-3475) when taken alone or in combination with other cancer treatments. The study will gather information on: ?The long-term safety of pembrolizumab or pembrolizumab-based combination treatments ?How well the drug(s) work ?How the body reacts to the drug(s) over the long term.

Detailed Description

This is a multi-center, open-label, Phase III study of pembrolizumab in participants with advanced or metastatic tumors. The purpose of this trial is to roll over participants who previously enrolled in MSD-sponsored pembrolizumab trials, including those who received pembrolizumab, pembrolizumab-based combinations or control, into an extension trial to collect long-term efficacy and safety data.

Eligibility Criteria

Inclusion Criteria

1. Participants are currently enrolled in MSD-sponsored pembrolizumab trials and are receiving trial treatment or in a follow-up phase at the time KN-587 is open. Participants must be from MSD-sponsored pembrolizumab parent trials established by the Sponsor as KN-587 transition-ready.

Exclusion Criteria

There are no exclusion criteria to participate in KN-587.

Keywords and/or Specific Medical Conditions

Oncology (Adult)

Sponsors

Merck & Company, Inc.